ATM与BRCA1/2胚系突变区分致死性与惰性前列腺癌风险并与较早死亡年龄相关
回顾性病例-病例研究纳入313例死于前列腺癌的患者与486例低危局限性前列腺癌患者,对799例患者的三基因胚系DNA进行测序。BRCA1/2与ATM合并突变携带率在致死性前列腺癌患者中为6.07%,高于局限性前列腺癌患者的1.44%(p=0.0007)。校正种族、年龄、前列腺特异性抗原与Gleason评分后,突变携带者仍为致死性前列腺癌的独立预测因素(风险比=2.13,95%置信区间:1.24-3.66,p=0.004)。
要点
- 致死性前列腺癌患者BRCA1/2与ATM合并突变携带率为6.07%,高于局限性前列腺癌患者的1.44%(p=0.0007)。
- 突变携带率随死亡年龄增大而下降,≤60岁为10.00%、61-65岁为9.08%、66-70岁为8.33%、71-75岁为4.94%、75岁以上为2.97%(p=0.046)。
- 校正种族、年龄、诊断时前列腺特异性抗原与Gleason评分后,突变携带者仍为致死性前列腺癌的独立预测因素(风险比=2.13,95%置信区间:1.24-3.66,p=0.004)。
核心结论
- BRCA1/2与ATM突变状态可区分致死性与惰性前列腺癌风险,并与较早死亡年龄和较短生存时间相关。
研究设计与样本
- 回顾性病例-病例研究,纳入313例死于前列腺癌的患者和486例低危局限性前列腺癌患者,共799例,涉及欧洲、非洲和中国血统。
- 对每例患者的三个基因(BRCA1/2与ATM)胚系DNA进行测序。
- 采用Fisher精确检验分析突变携带率,采用Cox回归分析突变对致死性前列腺癌的影响。
主要发现
- BRCA1/2与ATM合并突变携带率在致死性前列腺癌患者中为6.07%,高于局限性前列腺癌患者的1.44%(p=0.0007)。
- 致死性前列腺癌患者的突变携带率随死亡年龄不同而存在显著差异:≤60岁为10.00%、61-65岁为9.08%、66-70岁为8.33%、71-75岁为4.94%、75岁以上为2.97%(p=0.046)。
- 致死性前列腺癌患者的突变携带率随诊断后至死亡时间不同而存在显著差异:≤5年为12.26%、6-10年为4.76%、10年以上为0.98%(p=0.0006)。
- 全队列生存分析显示,校正种族、年龄、诊断时前列腺特异性抗原与Gleason评分后,突变携带者仍为致死性前列腺癌的独立预测因素(风险比=2.13,95%置信区间:1.24-3.66,p=0.004)。
关键数值与推荐
- 致死性前列腺癌患者BRCA1/2与ATM合并突变携带率为6.07%,局限性前列腺癌患者为1.44%(p=0.0007)。
- 致死性前列腺癌患者按死亡年龄≤60岁、61-65岁、66-70岁、71-75岁、75岁以上的突变携带率分别为10.00%、9.08%、8.33%、4.94%、2.97%(p=0.046)。
- 致死性前列腺癌患者按诊断后至死亡时间≤5年、6-10年、10年以上的突变携带率分别为12.26%、4.76%、0.98%(p=0.0006)。
- 校正种族、年龄、诊断时前列腺特异性抗原与Gleason评分后,突变携带者预测致死性前列腺癌的风险比=2.13(95%置信区间:1.24-3.66,p=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究的局限性在于未分析其他DNA修复基因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk. OBJECTIVE: To directly assess whether germline mutations in these three genes distinguish lethal from indolent PCa and whether they confer any effect on age at death. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-case study of 313 patients who died of PCa and 486 patients with low-risk localized PCa of European, African, and Chinese descent. Germline DNA of each of the 799 patients was sequenced for these three genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Mutation carrier rates and their effect on lethal PCa were analyzed using the Fisher's exact test and Cox regression analysis, respectively. RESULTS AND LIMITATIONS: The combined BRCA1/2 and ATM mutation carrier rate was significantly higher in lethal PCa patients (6.07%) than localized PCa patients (1.44%), p=0.0007. The rate also differed significantly among lethal PCa patients as a function of age at death (10.00%, 9.08%, 8.33%, 4.94%, and 2.97% in patients who died ≤ 60 yr, 61-65 yr, 66-70 yr, 71-75 yr, and over 75 yr, respectively, p=0.046) and time to death after diagnosis (12.26%, 4.76%, and 0.98% in patients who died ≤ 5 yr, 6-10 yr, and>10 yr after a PCa diagnosis, respectively, p=0.0006). Survival analysis in the entire cohort revealed mutation carriers remained an independent predictor of lethal PCa after adjusting for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis (hazard ratio=2.13, 95% confidence interval: 1.24-3.66, p=0.004). A limitation of this study is that other DNA repair genes were not analyzed. CONCLUSIONS: Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time. PATIENT SUMMARY: Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.
引用
- Na R, Zheng SL, Han M, et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2016. PMID: 27989354. doi:10.1016/j.eururo.2016.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。